Sunshine Biopharma (SBFM) Cash & Current Investments (2010 - 2026)

Sunshine Biopharma's Cash & Current Investments history runs 16 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• Quarterly Cash & Current Investments fell 15.64% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (down 15.64% YoY) and the FY2025 annual result came in at $9.1 million, down 5.81% from the prior year.
• Cash & Current Investments was $6.9 million for Q1 2026 at Sunshine Biopharma, down from $9.1 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $41.7 million in Q2 2022 and bottomed at $6.9 million in Q1 2026.
• A 5-year average of $16.8 million and a median of $13.2 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments surged 2294.89% — and 2023, when it plunged 53.54%.
• Sunshine Biopharma's Cash & Current Investments stood at $21.8 million in 2022, then fell by 25.35% to $16.3 million in 2023, then slumped by 40.55% to $9.7 million in 2024, then dropped by 5.81% to $9.1 million in 2025, then slipped by 24.23% to $6.9 million in 2026.
• Business Quant data shows SBFM's Cash & Current Investments at $6.9 million in Q1 2026, $9.1 million in Q4 2025, and $9.3 million in Q3 2025.